top of page

Protavio leads efforts on diagnostic tools for Chronic Kidney Disease

Protavio, and its affiliate company ProtATonce, teams up with leading scientists in Chronic Kidney Disease (CKD) and experts in mass spectrometry to improve diagnostic tools for clinical prognosis and diagnosis of the disease.*

Protavio develops diagnostics for Chronic Kidney Disease

CKD concerns the gradual deterioration of kidney function leading to kidney failure. CKD affects more than 10% of the population and imposes a considerable burden to the public health system especially for patients undergoing hemodialysis. Existing diagnostic methods are either invasive, unable to diagnose patients at early disease stages or limited in their prognostic power of disease progression. Novel, non-invasive diagnostic tools of high diagnostic performance are thus immediately needed and expected to greatly impact patient treatment efforts.

Protavio aims at the "Development of a Multiplex ELISA assay for the clinical prognosis and diagnosis of patients with Chronic Kidney Disease"* leveraging from the research efforts of the lab of Prof Antonia Vlahou at the Biomedical Research Foundation of the Academy of Athens. Prof Vlahou's team will also be responsible for the validation of the developed assay using state-of-the-art mass spectrometric approaches. The project will further benefit from the technical expertise and support in the field of mass spectrometry of two additional partners, Fasmatech and the Proteomics Facility ProFI of the Institute of Molecular Biology and Biotechnology, FORTH.

Protavio, a long-standing partner of Luminex Corporation, will use its expertise in the well-established Luminex xMAP technology to develop the Multiplex ELISA assays. Multiplexing technologies constitute a great advancement in the field of diagnostics by allowing the simultaneous analysis of multiple biomarkers from the same patient sample thus reducing the requirements for multiple sample collections and the cost of analysis. More importantly, they offer the ultimate platform when more than one biomarkers are required to reach the desired diagnostic power of the tool.

* The project is funded by the Research & Innovation Strategic Action as part of the 2014-2020 ESPA partnership agreement between the European Union and the Hellenic Republic.

Interested in our activities in CKD?

For any enquiries and questions write to us at:

For more information on the full spectrum of Protavio Services visit: